A spokesperson for Japanese company Kyowa Kirin, the licence holder of Pabrinex, said the closure of manufacturing facilities that would have required upgrading to comply with changes in EU regulations had affected the supply of the drug. The UK has experienced a dramatic recent rise in the number of unavailable drugs, with supply problems doubling from 648 in 2020 to 1,634 last year. A Nuffield Trust report in April found that while global manufacturing problems linked to Covid, inflation and the war in Ukraine had contributed to shortages, Brexit had exacerbated the situation in the UK. Read More